New research shows risankizumab delivers long-term psoriasis control, with OCT revealing reduced subclinical inflammation.

Over 52 weeks of treatment, risankizumab led to significant improvements in both clinical outcomes and optical coherence ...

At the 2nd International Glaucoma Symposium in Mainz, Germany, on 31 January 2026, optical coherence tomography (OCT) and its role in glaucoma and neuro-ophthalmic disease took centre stage in a ...

Optical Coherence Tomography (OCT) is a leading-edge imaging technology that is transforming medical diagnostics and research. It provides high-resolution cross-sectional images of biological tissues, ...

Risankizumab improved visible psoriasis and reduced subclinical vascular inflammation on optical coherence tomography over 52 ...

Endoscopic optical coherence tomography is widely used to visualize tissue microstructures in real time, but current probes ...